WO2005075002A1 - 医療用材料及びその製造方法 - Google Patents
医療用材料及びその製造方法 Download PDFInfo
- Publication number
- WO2005075002A1 WO2005075002A1 PCT/JP2005/001410 JP2005001410W WO2005075002A1 WO 2005075002 A1 WO2005075002 A1 WO 2005075002A1 JP 2005001410 W JP2005001410 W JP 2005001410W WO 2005075002 A1 WO2005075002 A1 WO 2005075002A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amniotic membrane
- cells
- epithelial
- membrane
- medical material
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
Definitions
- the present invention relates to a medical material and a method for producing the same, and more specifically, to a medical material using an amniotic membrane that has been subjected to a cross-linking treatment by bonding a biocompatible high molecular film and a method for producing the same.
- the cornea is a transparent tissue that does not include blood vessels, which is the outermost part of the optical system that constitutes the eyeball. Good visual acuity can be obtained because the cornea and tears form a smooth eyeball surface.
- keratoconjunctival epithelial cells are always in contact with the outside world, and foreign substances such as microorganisms in the outside world, and the light power such as ultraviolet rays, have a protective effect of protecting the eyeball.
- corneal conjunctival epithelial cells play an extremely important role in maintaining the transparency of the cornea, protecting the entire eyeball and maintaining homeostasis.
- Corneal transplantation has been used as a treatment for the loss of visual acuity caused by such corneal turbidity. Corneal transplantation involves removing the cornea of a patient who has lost transparency and replacing it with a new transparent cornea. By performing such a transplant, the transparency of the cornea can be restored, and visual acuity can be regained.
- the cornea is composed of epithelium (about 50 m thick), Bowman's membrane (about 10 m), stromal corneal layer (about 500 m), Descemet's membrane (about 10 m), and endothelial layer (about 5 m). It is composed of five layers and has a total thickness of 0.5 mm, with the corneal stromal layer accounting for 90% of the thickness.
- the cornea to be implanted must be both transparent and approximately 0.5 mm thick.
- a cornea having a non-uniform corneal thickness does not provide good visual acuity because it causes irregular astigmatism, which is also weak in intensity.
- the corneal epithelium functions to prevent bacteria from entering by covering the corneal surface and to maintain an optically smooth surface. The only cornea suitable for such transplantation is the donor-derived cornea.
- Non-Patent Documents 1 and 2 a transplantation method using amniotic membrane has been developed.
- the amniotic membrane used in this transplantation method can also obtain placental strength in pregnant women and the like who have undergone cesarean section.
- the amniotic membrane since the amniotic membrane has a thick basement membrane, it acts as a substrate for keratoconjunctival epithelial cells to proliferate and differentiate.
- amniotic membrane since amniotic membrane has an anti-inflammatory action and scar formation inhibiting action, which are almost immunogenic, the keratoconjunctival epithelium transplanted onto the amniotic membrane and these stem cell tissues may cause rejection of the transplant recipient (recipient). Protected from etc.
- the scar tissue of the eye on which the cornea has been removed is removed, and the cornea and the sclera are exposed.
- An amnion is stuck to the exposed cornea and sclera for ocular surface reconstruction.
- the provided corneal tissue was cut out of the central cornea (including epithelium, dermis and endothelium), trimmed around the limbal tissue, and transplanted onto the exposed amniotic membrane and corneal stroma. Will be met.
- the limbus transplanted in this manner is differentiated and proliferated using the amniotic membrane as a substrate while being protected by the non-immunogenic amniotic membrane, and the corneal epithelium is regenerated on the amniotic membrane.
- epithelial stem cells are preliminarily attached to an amniotic membrane and cultured in vitro, so that the epithelial cells cover the amnion surface.
- a method of growing cells see Patent Documents 15).
- Non-patent document 1 Medical Asahi September 1999 issue: p62-65
- Non-patent document 2 Kazuo Tsubota et al. N Engl J Med 340: 1697 Riki et al. 1703, 1999 Patent document 1: JP 2001-161353
- Patent Document 2 JP-A-2002-320666
- Patent Document 3 JP 2002-331025 A
- Patent Document 4 JP 2003-126236 A
- Patent Document 5 JP-T-2003-532466
- an implant using an amniotic membrane as a substrate has a thickness of less than 100 microns and has a layer corresponding to the corneal stroma, so that it is weak in strength. Although suitable for reconstructing the ocular surface, it is not suitable for thick transplants, including corneal stroma. In cases where the disease extends to the corneal stroma, further improvements in the amniotic transplantation method are needed.
- An object of the present invention is to provide a medical material capable of achieving higher therapeutic results in epithelial cells such as keratoconjunctival epithelial cells using amniotic membrane and a method for producing the same.
- the inventors of the present invention cultivated epithelial stem cells on the surface of a crosslinked amniotic membrane adhered to a biocompatible polymer membrane and obtained a biocompatible polymer membrane, an amniotic membrane, and an epithelial stem cell. Further, the present inventors have found that a medical material containing epithelial cells grown to cover the amniotic membrane from the cells can be obtained.
- the present invention includes an amniotic membrane, which is a placental tissue, a polymer membrane bonded to one surface of the amniotic membrane and subjected to a cross-linking treatment, and a cell adhered to the other surface of the amniotic membrane. Medical materials.
- the present invention provides a step of preparing an amniotic membrane from which a sponge layer has been removed, a step of bonding a biocompatible polymer film to one surface of the amniotic membrane and performing a cross-linking treatment, and the other step of the aforementioned amniotic membrane.
- the method for producing a medical material as described above comprising a step of attaching epithelial stem cells to the surface and a step of growing epithelial cells from the epidermal stem cells to the amniotic membrane surface.
- the biocompatible polymer membrane Since the biocompatible polymer membrane has high biocompatibility, the engraftment rate after transplantation of the graft is higher than in the case where the biocompatible polymer membrane is not used. Further, since the biocompatible polymer membrane is transparent and can be appropriately changed in thickness, it is particularly effective for transplantation of corneal epithelium or conjunctival epithelium and corneal stroma.
- amniotic membrane is the innermost membrane of the vertebrate amniotes (Amniota: reptiles, birds, mammals) formed during the developmental process and directly covers the embryo.
- Amniotic membrane is a suitable material for transplantation because it has a thick basement membrane and does not express histocompatibility antigens on the cell surface, and has an anti-inflammatory effect with almost no immunogenicity.
- amniotic membrane has almost no immunogenicity, but the animal species to which the medical material of the present invention is transplanted in order to more reliably prevent the induction of an immune response after transplantation and to prevent interspecies infection. It is desirable to use an amniotic membrane from the same animal.
- amniotic membrane in order to produce a medical material for transplantation into humans, it is desirable to use human amniotic membrane.
- an amniotic membrane derived from the same animal species as the animal into which the graft is transplanted it is not limited to those having a kin relationship such as a parent and a child, and those of another person can be used.
- Human-derived amniotic membrane can be obtained by cesarean section of a pregnant woman. If it is not from a pregnant woman undergoing a cesarean section, it is generally difficult to use because of the potential for contamination.
- the amniotic membrane generally has a sponge layer (sponge layer), a compact layer, a basement membrane layer, and an epithelial layer from the lower side, but the amniotic membrane used for the medical material of the present invention is composed of the sponge layer and the upper layer. It is desirable to use a skin layer that has been removed in advance.
- "amniotic membrane” means an amniotic membrane from which a sponge layer and an epithelial layer have been removed.
- the amniotic membrane from which the sponge layer and the epithelial layer have been removed is bonded to a biocompatible polymer membrane and subjected to a bridge bonding treatment.
- the biocompatible polymer membrane that can be used in the present invention may be a biopolymer, a synthetic polymer, or a hybrid thereof.
- Biopolymers include proteins, glycosaminodalican, proteodalican, alginic acid, chitosan, polyamino acids, or a combination of two or more of these.
- Glycosaminodalican includes chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparan sulfate, heparin, keratan sulfate, or derivatives thereof.
- the protein include collagen, atelocollagen, alkali-treated collagen, gelatin, keratin, serum albumin, ovalbumin, hemoglobin, casein and globulin, fibrinogen, and derivatives thereof.
- the synthetic polymer used for the biocompatible polymer membrane include a polymer of a water-soluble monomer or a water-soluble polymer.
- Water-soluble monomers include n-isopropylacrylamide, acrylamide, acrylic acid, methacrylic acid, burpyrrolidone or a combination of two or more thereof. Further, as the water-soluble polymer, one or two or more of polyvinyl alcohol (PVA), polyallylamine, polybulamine, aliphatic and aromatic diisocyanates, PVA having an amino group introduced by CNBr, or two or more of these Combinations are possible.
- PVA polyvinyl alcohol
- polyallylamine polyallylamine
- polybulamine polybulamine
- aliphatic and aromatic diisocyanates PVA having an amino group introduced by CNBr, or two or more of these Combinations are possible.
- the collagen film is preferably a crosslinked product of alkali-treated type I collagen.
- Such a film is preferably made of, for example, swine skin-derived alkali-treated type I collagen available from NITTA GELATIN Inc. Can be used. Collagen has more than a dozen types of forces, independent of these types and origins.
- One type of cross-linking between the amniotic membrane and the biocompatible polymer membrane is immobilization by covalent bonding. This can be performed by performing a cross-linking treatment in the presence of a cross-linking agent such as daltaraldehyde or formaldehyde and collagen or gelatin. This processing can be specifically performed by the following steps.
- an amniotic membrane is spread on a glass plate, and a mixed solution of a crosslinking agent and collagen is applied thereto. Thereafter, by mounting the biocompatible polymer membrane, a cross-linking reaction occurs between the amniotic membrane and the biocompatible polymer membrane, and the amniotic membrane can be fixed. Further, alternatively, the cross-linking treatment can be performed by applying only a cross-linking agent to the amniotic membrane and reacting the amniotic membrane with the biocompatible polymer membrane. Since such a cross-linking is a covalent cross-linking, it has a feature that the amniotic membrane and the biocompatible membrane are stably present without peeling off even in a physiological environment.
- the epithelial stem cells adhered onto the amniotic membrane cross-linked with the biocompatible polymer membrane are capable of cell division to generate epithelial tissue cells.
- the epithelial cells used include corneal epithelial cells and conjunctival epithelial cells.
- the stem cells of the corneal epithelial cells that divide and give rise to the corneal epithelium are present in the limbus.
- stem cells of conjunctival epithelial cells that undergo cell division to generate conjunctival epithelium are present in the conjunctival fornix and the like. These These cells can be removed from the living body by cutting out the tissue at the site where the cells are present.
- the removed cells are directly placed on the amniotic membrane, or only the cells are removed by treating the cut tissue with an enzyme such as trypsin or dispase, and the cells are seeded on the amniotic membrane. It can be attached on the amniotic membrane by such a method. Cells that have adhered to the amniotic membrane can be, for example, in the presence of feeder layer cells.
- DMEM / F12 liquid medium with 15% by volume serum and cholera toxin, epidermal growth factor, insulin, dimethyl sulfoxide-added medium, etc. it is possible to grow on amniotic membrane.
- Epithelial cells stratified in the same way as the cornea of living organisms are cultured by growing the cells that have grown to cover the entire amniotic membrane, and reducing the volume of the culture medium until the cells are exposed to air. It can be obtained by doing.
- the limbus is used as an epithelial stem cell tissue
- the conjunctival rim or the like is used as the epithelial stem cell. It can be used as a medical material.
- Epithelial stem cell tissues such as the limbus or conjunctival margin containing epithelial stem cells include epithelial cells, fibroblasts, and vascular endothelial cells in addition to stem cells, even if they are substantially only stem cells. May be included.
- the epithelial stem cell tissue may be obtained either from the relatives of the recipient of the transplant (recipient) or may be obtained from others who are completely related to the recipient. When obtaining epithelial stem cells other than the recipient, those derived from an HLA-type-compatible donor are preferable in order to avoid the possibility of immune rejection.
- epithelial stem cells derived from a donor whose HLA type is compatible cannot be obtained, epithelial stem cells derived from a donor whose HAL type is compatible may be used.
- epithelial stem cells derived from a donor whose HAL type is compatible may be used.
- tissue provided that has been confirmed in advance that there is no fear of infection or the like.
- the epithelial stem cells those obtained by the recipient of the transplant (recipients) themselves can be used as long as they are determined to contain stem cells.
- the epithelial stem cell tissue is preferably one that can proliferate epithelial cells whose condition is poor.
- the size of the stem cell tissue from which the donor or recipient's own power is also extracted is, for example, When the condition of the stem cell tissue is good, it may be about 1 mm square for a 2 cm square amniotic membrane. The size of the excised stem cell tissue can be appropriately changed according to the state of the cells, the degree of the disease of the recipient, and the like.
- the epithelial stem cell tissue cut out from the donor is adhered onto an amniotic membrane that has been cross-linked with a biocompatible polymer membrane.
- an amniotic membrane that has been cross-linked with a biocompatible polymer membrane.
- the epithelial stem cell tissue is a limbus
- the epithelial stem cell be molded into a size about the size of the recipient's cornea and arranged in a shape close to a ring.
- Epidermal stem cells placed on a cross-linked amniotic membrane adhered to a biocompatible polymer membrane are exposed to air in vitro after the amniotic membrane and the stem cells are immersed in a culture solution in vitro.
- the epithelium can be stratified by exposing the epithelium.
- the epithelial cells include stem cells contained in the epithelial stem cell tissue that have proliferated by cell division, but also arise from cell division of epithelial cells other than the stem cells contained in the provided epithelial stem cell tissue. May be included.
- epithelial cells are proliferated and differentiated on the amniotic membrane from the (epithelial) stem cells so as to cover the amniotic membrane surface, and preferably the stratification of the epithelial cells is promoted.
- epithelial stem cell tissue which does not undergo proliferation in vitro, may be transplanted to a recipient in a state where it is adhered to the amniotic membrane, and epithelial cells may be propagated in the affected area of the recipient.
- epithelial cells grown on amniotic membrane are desired to be in a good condition at the time of transplantation.
- cells in the logarithmic growth phase have a constant metabolic activity.
- Cells that are maintained in a stable manner and are repeatedly dividing at a constant cell cycle are preferred.
- the medical material containing the epithelial stem cell tissue adhered to the surface and the stem cell tissue-proliferated epithelial cells is transplanted together with the epithelial cells to the affected area where the stem cell tissue has been eradicated or damaged.
- Glutaraldehyde is added Caro to a final concentration of 6mM in dimethyl sulfoxide collagen (DMSO) solution (30 wt 0/0), the silicone rubber of the mixed solution thickness 500 m and spacer one The mixture was poured between two glass plates and reacted at 37 ° C. for 24 hours to obtain a collagen gel sheet. Thereafter, DMSO was replaced by immersing the gel sheet in a large excess of a phosphate buffer.
- DMSO dimethyl sulfoxide collagen
- a water / DMSO mixed solvent solution (15% by volume) of PVA (average degree of polymerization: 77,000) was dissolved in an autoclave at 120 ° C. for 5 hours. The solution was poured between two glass plates of 200-500 m thick silicone rubber as a spacer, left in a freezer at 20 ° C for 2 hours, and thawed at room temperature to obtain a PVA gel sheet . Then, put the PVA gel sheet and lyophilized 10 weight 0/0 toluene solution of hexamethylene diisocyanate to tin catalysts containing a nitrogen Baburi ring, Isoshiana one preparative groups PVA gel sheet surface by stirring at room temperature for one hour Was introduced. The gel sheet was immersed in a large excess of a phosphate buffer to convert isocyanate groups to amino groups.
- 3T3 cells treated with mitomycin C were seeded in a well below a transwell. Thereafter, the limbus cut out from the human cornea for transplantation provided by a foreign donor was treated with 0.05% by weight of trypsin EDTA at 37 ° C for 1 hour to separate epithelial cells including stem cells.
- the collagen gel sheet immobilized on the amniotic membrane and the PVA gel sheet immobilized on the amniotic membrane obtained in the above step 2 are respectively placed in the upper well of the transwell.
- the amniotic membrane was placed on top, and epithelial cells were seeded on it and cultured on the amniotic membrane surface until the cells completely covered the surface.
- the stratification of the epithelial layer was performed by reducing the volume of the medium until the surface of the epithelial cells was exposed to air and culturing for 2 weeks.
- FIG. 2 shows an optical micrograph (HE staining) of a cross section of corneal epithelial cells layered on an amniotic membrane-immobilized collagen gel sheet.
- FIG. 3 shows an optical micrograph (HE staining) of a cross section of corneal epithelial cells layered and cultured on an amniotic membrane PVA gel sheet. It can be seen that a uniform corneal epithelial layer having a thickness of about 50 microns was formed.
- FIG. 1 An optical micrograph as a substitute for a drawing showing a cross section of an amnion-immobilized collagen gel of Example 1.
- FIG. 2 is an optical microscope photograph (HE staining) as a substitute for a drawing, showing a cross section of corneal epithelial cells layered and cultured on an amniotic membrane-collagen gel sheet according to the method of Example 1.
- FIG. 3 is an optical micrograph (HE staining) as a substitute for a drawing, showing a cross section of corneal epithelial cells layered and cultured on an amniotic membrane PVA gel sheet by the method of Example 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/588,309 US20070254013A1 (en) | 2004-02-04 | 2005-02-01 | Medical Material and Process for Producing the Same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004028581A JP2005218585A (ja) | 2004-02-04 | 2004-02-04 | 医療用材料及びその製造方法 |
JP2004-028581 | 2004-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005075002A1 true WO2005075002A1 (ja) | 2005-08-18 |
Family
ID=34835928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001410 WO2005075002A1 (ja) | 2004-02-04 | 2005-02-01 | 医療用材料及びその製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20070254013A1 (ja) |
JP (1) | JP2005218585A (ja) |
WO (1) | WO2005075002A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007010305A2 (en) * | 2005-07-15 | 2007-01-25 | The University Of Nottingham | Surgical membrane |
JP2009544313A (ja) * | 2006-07-24 | 2009-12-17 | インターナショナル ステム セル コーポレイション | 網膜幹細胞由来の合成角膜 |
US9084767B2 (en) | 2007-09-07 | 2015-07-21 | Mimedx Group, Inc. | Placental tissue grafts and methods of preparing and using the same |
US9956253B2 (en) | 2006-08-17 | 2018-05-01 | Mimedx Group, Inc. | Placental tissue grafts |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080070820A (ko) * | 2005-10-12 | 2008-07-31 | 셀룰라 바이오엔지니어링 인코포레이티드 | 재흡수성 각막편 |
RU2008137975A (ru) * | 2006-02-24 | 2010-03-27 | Релайанс Лайф Сайенсиз Пвт Лтд. (In) | Конъюнктивальная тканевая система |
US9480549B2 (en) | 2008-04-25 | 2016-11-01 | Allosource | Multi-layer tissue patches |
US9358320B2 (en) | 2008-04-25 | 2016-06-07 | Allosource | Multi-layer tissue patches |
KR20110013419A (ko) * | 2008-04-25 | 2011-02-09 | 알로소스 | 가공된 양막 조직을 포함하는 유착 방지 배리어 상처 드레싱 및 이를 사용하는 방법 |
KR101372966B1 (ko) * | 2009-01-23 | 2014-03-13 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 표적 세포 유도용 피더 세포 |
US20110293691A1 (en) * | 2010-04-28 | 2011-12-01 | Weber Kurt R | Multimodal adhesion barrier |
US9574171B2 (en) * | 2010-12-02 | 2017-02-21 | Technion Research & Development Foundation Ltd. | Methods of generating corneal cells and cell populations comprising same |
AU2015206236B2 (en) | 2014-01-17 | 2020-02-20 | Mimedx Group, Inc. | Method for inducing angiogenesis |
EP3185918B1 (en) * | 2014-08-28 | 2021-08-18 | MiMedx Group, Inc. | Collagen reinforced tissue grafts |
CN114028618A (zh) * | 2021-10-25 | 2022-02-11 | 广东普洛宇飞生物科技有限公司 | 一种基于羊膜基底膜的生物材料及其制备方法和应用 |
CN115337326B (zh) * | 2022-08-22 | 2023-10-27 | 赛克赛斯生物科技股份有限公司 | 一种载药羊膜、其制备方法及在制备眼科疾病医用材料方面的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08266613A (ja) * | 1995-03-31 | 1996-10-15 | Toyobo Co Ltd | 医用材料およびその製造方法 |
JPH09122227A (ja) * | 1995-10-31 | 1997-05-13 | Bio Eng Lab:Kk | 医用材料およびその製造方法 |
JP2001161353A (ja) * | 1999-12-09 | 2001-06-19 | Japan Ophthalmic Consultants:Kk | 移植用細胞片及びその作成方法 |
JP2003190192A (ja) * | 2001-12-28 | 2003-07-08 | Japan Science & Technology Corp | 末梢神経再生方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0734736A1 (en) * | 1995-03-31 | 1996-10-02 | Toyo Boseki Kabushiki Kaisha | Medical device and method for producing the same |
-
2004
- 2004-02-04 JP JP2004028581A patent/JP2005218585A/ja active Pending
-
2005
- 2005-02-01 US US10/588,309 patent/US20070254013A1/en not_active Abandoned
- 2005-02-01 WO PCT/JP2005/001410 patent/WO2005075002A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08266613A (ja) * | 1995-03-31 | 1996-10-15 | Toyobo Co Ltd | 医用材料およびその製造方法 |
JPH09122227A (ja) * | 1995-10-31 | 1997-05-13 | Bio Eng Lab:Kk | 医用材料およびその製造方法 |
JP2001161353A (ja) * | 1999-12-09 | 2001-06-19 | Japan Ophthalmic Consultants:Kk | 移植用細胞片及びその作成方法 |
JP2003190192A (ja) * | 2001-12-28 | 2003-07-08 | Japan Science & Technology Corp | 末梢神経再生方法 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007010305A3 (en) * | 2005-07-15 | 2008-01-10 | Univ Nottingham | Surgical membrane |
GB2441939A (en) * | 2005-07-15 | 2008-03-19 | Univ Nottingham | Surgical membrane |
GB2441939B (en) * | 2005-07-15 | 2011-03-16 | Univ Nottingham | Surgical membrane |
WO2007010305A2 (en) * | 2005-07-15 | 2007-01-25 | The University Of Nottingham | Surgical membrane |
JP2009544313A (ja) * | 2006-07-24 | 2009-12-17 | インターナショナル ステム セル コーポレイション | 網膜幹細胞由来の合成角膜 |
US9956253B2 (en) | 2006-08-17 | 2018-05-01 | Mimedx Group, Inc. | Placental tissue grafts |
US11504449B2 (en) | 2006-08-17 | 2022-11-22 | Mimedx Group, Inc. | Placental tissue grafts and methods of preparing and using the same |
US10406259B2 (en) | 2006-08-17 | 2019-09-10 | Mimedx Group, Inc. | Placental tissue grafts and improved methods of preparing and using the same |
US9272003B2 (en) | 2007-09-07 | 2016-03-01 | Mimedx Group, Inc. | Placental tissue grafts |
US9789137B2 (en) | 2007-09-07 | 2017-10-17 | Mimedx Group, Inc. | Placental tissue grafts and improved methods of preparing and using the same |
US9533011B2 (en) | 2007-09-07 | 2017-01-03 | Mimedx Group, Inc. | Placental tissue grafts and methods of preparing and using the same |
US9415074B2 (en) | 2007-09-07 | 2016-08-16 | Mimedx Group, Inc. | Placental tissue grafts |
US10874697B2 (en) | 2007-09-07 | 2020-12-29 | Mimedx Group, Inc. | Placental tissue grafts and improved methods of preparing and using the same |
US9084767B2 (en) | 2007-09-07 | 2015-07-21 | Mimedx Group, Inc. | Placental tissue grafts and methods of preparing and using the same |
US11752174B2 (en) | 2007-09-07 | 2023-09-12 | Mimedx Group, Inc. | Placental tissue grafts and improved methods of preparing and using the same |
Also Published As
Publication number | Publication date |
---|---|
JP2005218585A (ja) | 2005-08-18 |
US20070254013A1 (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005075002A1 (ja) | 医療用材料及びその製造方法 | |
Chen et al. | Biomaterials for corneal bioengineering | |
JP5946046B2 (ja) | ヒト角膜内皮細胞シート | |
Mahdavi et al. | Bioengineering approaches for corneal regenerative medicine | |
US5713957A (en) | Corneal onlays | |
Myung et al. | Development of hydrogel‐based keratoprostheses: A materials perspective | |
CA2848405C (en) | Fabrication of gelatin hydrogel sheet for the transplantation of corneal endothelium | |
KR101319227B1 (ko) | 각막 내피세포 및 관련세포를 생체고분자 위에서성장시키고, 인공의 이식용 각막을 제조하는 방법 및조성물 | |
Griffith et al. | Regenerative approaches as alternatives to donor allografting for restoration of corneal function | |
P De Miguel et al. | Cornea and ocular surface treatment | |
JP4397082B2 (ja) | 移植用細胞片及びその作成方法 | |
JPWO2005087286A1 (ja) | 生体組織シート及びその作製方法、並びに同シートを用いる移植方法 | |
WO2019198086A1 (en) | Bioengineered corneal graft and methods of preparation thereof | |
WO2007043255A1 (ja) | 培養角膜内皮シート及びその作製方法 | |
Lai et al. | Functional biomedical polymers for corneal regenerative medicine | |
WO2005087285A1 (ja) | 角膜上皮シート及びその作製方法、並びに同シートを用いる移植方法 | |
US20040096505A1 (en) | Hydrogel membrane composition and use thereof | |
CA2174967C (en) | Corneal onlays | |
JP4874514B2 (ja) | 上皮系細胞の重層化培養方法、それから得られる重層化上皮系細胞シート及びその利用方法 | |
JP3935096B2 (ja) | 高生着性角膜上皮代替細胞シート、製造方法及びその利用方法 | |
KR20160140494A (ko) | 각막 탈세포화 세포외 기질을 함유하는 각막 유래 세포의 지지체 및 이를 포함하는 인공 각막 시트 | |
Grolik et al. | Silicone-modified chitosan membranes for corneal epithelium tissue engineering | |
McCulley et al. | In vitro transfer of rabbit corneal epithelium from carriers to denuded corneas or cryolathed lenticules | |
AU682907B2 (en) | Corneal onlays | |
Venugopal et al. | Stem cell–based therapeutic approaches toward corneal regeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10588309 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10588309 Country of ref document: US |